Aura Biosciences Files Q2 2024 10-Q
Ticker: AURA · Form: 10-Q · Filed: 2024-08-08T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Aura Biosciences dropped its Q2 10-Q. Check financials.
AI Summary
Aura Biosciences, Inc. filed its 10-Q for the period ending June 30, 2024. The company, focused on biological products, reported financial information for the second quarter. Key financial data and operational details are included in this filing.
Why It Matters
This filing provides investors and stakeholders with the latest financial performance and operational updates for Aura Biosciences, crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Aura Biosciences faces inherent risks related to research, development, regulatory approvals, and market adoption of its products.
Key Numbers
- Q2 2024 — Reporting Period (The financial period covered by the 10-Q filing.)
- June 30, 2024 — End Date (The specific date marking the end of the reporting quarter.)
Key Players & Entities
- Aura Biosciences, Inc. (company) — Filer of the 10-Q
- 0000950170-24-093308 (filing_id) — Accession Number for the filing
- 20240630 (date) — Period of report for the 10-Q
- 20240808 (date) — Filing date of the 10-Q
- Boston, MA (location) — Company's business and mailing address
- National Institute of Health (company) — Mentioned in relation to grants or funding
FAQ
What is the primary business of Aura Biosciences, Inc.?
Aura Biosciences, Inc. is primarily involved in Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted on August 8, 2024.
What is the fiscal year end for Aura Biosciences, Inc.?
The fiscal year end for Aura Biosciences, Inc. is December 31.
Where is Aura Biosciences, Inc. located?
Aura Biosciences, Inc. is located in Boston, MA, with its business and mailing address at 80 Guest Street.
What is the SEC file number for Aura Biosciences, Inc.?
The SEC file number for Aura Biosciences, Inc. is 001-40971.
Filing Stats: 4,438 words · 18 min read · ~15 pages · Grade level 18.9 · Accepted 2024-08-08 07:10:26
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share AURA Nasdaq Global Market
Filing Documents
- aura-20240630.htm (10-Q) — 2090KB
- aura-ex3_1.htm (EX-3.1) — 64KB
- aura-ex10_1.htm (EX-10.1) — 21KB
- aura-ex31_1.htm (EX-31.1) — 17KB
- aura-ex31_2.htm (EX-31.2) — 17KB
- aura-ex32_1.htm (EX-32.1) — 15KB
- 0000950170-24-093308.txt ( ) — 8187KB
- aura-20240630.xsd (EX-101.SCH) — 1194KB
- aura-20240630_htm.xml (XML) — 1280KB
Financial Statements (Unaudited)
Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Stockholders' Equity 3 Condensed Consolidated Statements of Cash Flows 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 16 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 26 Item 4.
Controls and Procedures
Controls and Procedures 26 PART II. OTHER INFORMATION 27 Item 1.
Legal Proceedings
Legal Proceedings 27 Item 1A.
Risk Factors
Risk Factors 27 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 72 Item 3. Defaults Upon Senior Securities 72 Item 4. Mine Safety Disclosures 73 Item 5. Other Information 73 Item 6. Exhibits 74
Signatures
Signatures 75 iii PA RT I—FINANCIAL INFORMATION
Fina ncial Statements
Item 1. Fina ncial Statements. Aura Biosciences, Inc. Condensed Cons olidated Balance Sheets (Unaudited) (in thousands, except share and per share amounts) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 30,075 $ 41,063 Marketable securities 157,341 185,087 Restricted cash and deposits — 19 Prepaid expenses and other current assets 8,180 5,625 Total current assets 195,596 231,794 Restricted cash and deposits, net of current portion 768 768 Right of use assets - operating lease 18,141 18,854 Other long-term assets 443 509 Property and equipment, net 3,334 3,150 Total Assets $ 218,282 $ 255,075 Liabilities and Stockholders' Equity Current liabilities: Accounts payable 1,459 1,787 Short-term operating lease liability 2,754 2,687 Accrued expenses and other current liabilities 6,335 7,883 Total current liabilities 10,548 12,357 Long-term operating lease liability 16,280 16,870 Total Liabilities 26,828 29,227 Commitments and Contingencies (Note 12) Stockholders' Equity: Common stock, $ 0.00001 par value, 150,000,000 authorized at June 30, 2024 and December 31, 2023, and 49,583,358 and 49,350,788 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively — — Additional paid-in capital 518,988 512,617 Accumulated deficit ( 327,351 ) ( 287,308 ) Accumulated other comprehensive loss ( 183 ) 539 Total Stockholders' Equity 191,454 225,848 Total Liabilities and Stockholders' Equity $ 218,282 $ 255,075 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 1 Aura Biosciences, Inc. Condensed Cons olidated Statements of Operations and Comprehensive Loss (Unaudited) (in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2024 2023 2024